Mentari Therapeutics appoints Deloitte as auditor
MTRI•Mentari Therapeutics appointed Deloitte & Touche as auditor for the fiscal year ending December 31, 2026, after dismissing its two previous auditors on November 17. Their reports cited substantial doubt about their respective clients’ ability to continue as going concerns.
1. Auditor appointment
Mentari Therapeutics engaged Deloitte & Touche on November 19, 2026, as auditor for the fiscal year ending December 31, 2026. Two days earlier, it dismissed CBIZ, InMed’s pre-merger auditor, and Ernst & Young, Mentari’s pre-merger auditor.
2. Outgoing auditors
Neither outgoing auditor had accounting disagreements or reportable events during the periods reviewed through November 17, 2026. Both auditors’ reports included explanatory paragraphs citing substantial doubt about their respective clients’ ability to continue as going concerns.




